ACS chemical neuroscience molecule spotlight on suvorexant

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.

Original languageEnglish (US)
Pages (from-to)647-648
Number of pages2
JournalACS Chemical Neuroscience
Issue number9
StatePublished - Sep 19 2012
Externally publishedYes


  • Sleep
  • bioavailability (F)
  • insomnia
  • novel mechanism
  • orexin antagonist

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on suvorexant'. Together they form a unique fingerprint.

Cite this